Latest ERT Stories

Majority of biopharma executives believe Strategic Partnerships positively impact their engagement with CROs BOSTON, April 22, 2013 /PRNewswire/ -- PAREXEL International (NASDAQ: PRXL), a leading global biopharmaceutical services organization, today released a new research report called Strategic Partnerships 2013 at the 22(nd) Annual Partnerships in Clinical Trials Conference in Orlando, FL. The report is the first to explore the current outsourcing landscape and the value Strategic...

Appointment also further strengthens growing Pharmacovigilance practice KAISERSLAUTERN, Germany, April 15, 2013 /PRNewswire/ -- pharma solutions international GmbH (pharmaSOL) announced today the appointment of Dr. Marc A. Zittartz to the position of Chief Strategy Officer, starting June 1st, 2013. In this role, he will be responsible for developing and implementing pharmaSOL's strategy to deliver innovative technology solutions, GxP compliant cloud hosting and expert consulting...

FORT WASHINGTON, Pa. and TOKYO, March 27, 2013 /PRNewswire/ -- ReSearch Pharmaceutical Services Inc. ("RPS"), a leading global contract research organization (CRO), and Asklep Inc. ("Asklep"), one of Japan's largest CROs, today announced the creation of a Joint Venture Company (JVC) to deliver leading-edge R&D outsourcing solutions in Japan to the biopharmaceutical and medical device industries. The exclusive RPS-Asklep collaboration will leverage RPS' proprietary structures...

Scientists to Share Knowledge of High-Quality Patient Safety and Efficacy Data Collection PHILADELPHIA, PA – March 25, 2013 (PRWEB) March 25, 2013 -- ERT, a leading global provider of high-quality patient safety and efficacy data collection solutions for use in clinical drug development, today announced a series of upcoming industry conferences and company-sponsored events that will feature presentations by members of ERT’s scientific and regulatory teams. ERT’s scientists will...

Worldwide Life Science Drug Safety Services 2013 Vendor Assessment Chennai, India (PRWEB) March 20, 2013 TAKE Solutions Ltd. [BSE: 532890 | NSE: TAKE], a leader in the Life Sciences (LS) and Supply Chain Management (SCM) domains, announced today that it has received a 'Leader' rating in IDC Health Insights' “IDC MarketScape: Worldwide Life Science Drug Safety Services 2013 Vendor Assessment". The IDC MarketScape assessment evaluated leading drug safety services (DSS)...

SAN DIEGO, March 13, 2013 /PRNewswire/ -- Orexigen(®) Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity, today announced financial results for the fourth quarter and year ended December 31, 2012. Three months ended December 31, 2012For the three months ended December 31, 2012, Orexigen reported a net loss of $32.5 million, or $0.41 per share, as compared to a net loss of $4.3 million, or $0.09 per share, for the fourth quarter of...

ROCKVILLE, Md., March 6, 2013 /PRNewswire-USNewswire/ -- Accelovance, Inc. announced today the acquisition of Radiant Development, the CRO division of Radiant Research. This is the latest development in an expansion strategy by the Maryland based CRO that caters to Biotech and small/mid Pharma Sponsors. Terms of the transaction were not disclosed. Accelovance is a patient centric CRO offering innovative solutions to meet the needs of its clients. Much of the company's CRO growth...

Exhibit Will Feature Demonstrations of the Company's Effective, Non-Invasive Treatment for Heart Disease and Diagnostic Products WESTBURY, N.Y., Feb. 26, 2013 /PRNewswire/ -- In continuing to spread awareness of the benefits of alternative treatments for heart disease, Vasomedical, Inc. ("Vasomedical") (OTC BB: VASO), a diversified medical technology company specializing in the design, manufacture and sale of medical devices for noninvasive cardiology including EECP(®) Therapy...

HYDERABAD, India, Feb. 13, 2013 /PRNewswire/ -- Neuland Laboratories Ltd., (NSE:NEULANDLAB; BOM:524558) a pharmaceutical manufacturer providing active pharmaceutical ingredients (APIs), complex intermediates and contract manufacturing services to customers located in 85 countries, today announced financial results for the third quarter of fiscal year (FY) 2013, ended December 31, 2012. Revenues for the third quarter of FY 2013 were $19.56 million (1.074 billion INR*), compared to...

SUNNYVALE, Calif., Feb. 7, 2013 /PRNewswire/ -- Pharmacyclics, Inc. (the "Company") (Nasdaq: PCYC) today announced that it will report financial results and recent developments for its three and six months ended December 31, 2012 after the NASDAQ Market closes on Thursday, February 14, 2013. The Company will conduct a conference call and audio webcast at 4:30 p.m ET on the same day. As previously announced, the Company changed its fiscal year end from June 30 to December 31,...